Newsroom
Press Releases
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and…
Read More
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control…
Read More
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330…
Read More
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in…
Read More
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly…
Read More
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Read MoreUCB Stories
Evolving Expectations in Immunologic Disease: Our work with those living with immune-mediated…
Read More
3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time
Read More
Innovation Equals Access: How UCB Delivered for Patients in 2025
Read More
More than Medicine: UCB's Holistic Approach to Supporting MG Patients
Read More
Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program
Read More
